| CEO Name | David R. Epstein |
| Nationality | United States |
| Net Worth Estimation | $150 million |
David R. Epstein's estimated net worth of around $150 million primarily stems from his executive compensation, bonuses, and substantial stock holdings acquired through his leadership roles at Novartis, Intercept Pharmaceuticals, and as CEO of Seagen. His wealth is further bolstered by equity grants awarded during Seagen's high-valuation period and the company's acquisition by Pfizer.
David R. Epstein, CEO of Seagen, has an estimated net worth of $150,000,000, which is 87.5% higher than the maximum estimated range ($80,000,000) for CEOs in the biotechnology sector. His net worth is 15 times the minimum estimated for biotech CEOs ($10,000,000).
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
David R. Epstein Performance in Seagen (formerly Seattle Genetics)
David R. Epstein, CEO of Seagen (formerly Seattle Genetics), is recognized for strategic leadership in oncology biopharmaceuticals, driving innovation in antibody-drug conjugates. His decisive management enhanced R&D productivity and successfully led key product launches, significantly boosting company growth and market valuation. Epstein's performance solidified Seagen's position as a leading cancer therapy developer, expanding its pipeline and global partnerships.
Latest News
Seagen Names Former Novartis Oncology Chief David Epstein as CEO Amid Leadership Transition
After founder and former CEO Clay Siegall resigned following a domestic abuse arrest, Seagen appointed David Epstein, a veteran from Novartis Oncology, as its new CEO to lead the company forward. Epstein, who has extensive experience growing Novartis's oncology business, took over Seagen, formerly Seattle Genetics, during a period of strategic changes including its acquisition by Pfizer.
Source: http://www.fiercepharma.com/pharma/transition-and-tumult-seagen-names-former-novartis-oncology-chief-epstein-new-ceo